dc.contributor.author | Eliassen, A. Heather | |
dc.contributor.author | Spiegelman, Donna | |
dc.contributor.author | Xu, Xia | |
dc.contributor.author | Keefer, Larry K. | |
dc.contributor.author | Veenstra, Timothy D. | |
dc.contributor.author | Barbieri, Robert L. | |
dc.contributor.author | Willett, Walter C.::94559ea206eef8a8844fc5b80654fa5b::600 | |
dc.contributor.author | Hankinson, Susan E. | |
dc.contributor.author | Ziegler, Regina G. | |
dc.date.accessioned | 2019-09-21T16:12:40Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Eliassen, A. H., D. Spiegelman, X. Xu, L. K. Keefer, T. D. Veenstra, R. L. Barbieri, W. C. Willett, S. E. Hankinson, and R. G. Ziegler. 2011. “Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer among Premenopausal Women.” Cancer Research 72 (3): 696–706. https://doi.org/10.1158/0008-5472.can-11-2507. | |
dc.identifier.issn | 0008-5472 | |
dc.identifier.issn | 1538-7445 | |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384797 | * |
dc.description.abstract | Endogenous estrogens and estrogen metabolism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited. We examined 15 urinary estrogens/estrogen metabolites and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II (NHSII). From 1996 to 1999, urine was collected from 18,521 women during the mid-luteal menstrual phase. Breast cancer cases (N = 247) diagnosed between collection and June 2005 were matched to two controls each (N = 485). Urinary estrogen metabolites were measured by liquid chromatography-tandem mass spectrometry and adjusted for creatinine level. Relative risks (RR) and 95% confidence intervals (CI) were estimated by multivariate conditional logistic regression. Higher urinary estrone and estradiol levels were strongly significantly associated with lower risk (top vs. bottom quartile RR: estrone = 0.52; 95% CI, 0.30-0.88; estradiol = 0.51; 95% CI, 0.30-0.86). Generally inverse, although nonsignificant, patterns also were observed with 2- and 4-hydroxylation pathway estrogen metabolites. Inverse associations generally were not observed with 16-pathway estrogen metabolites and a significant positive association was observed with 17-epiestriol (top vs. bottom quartile RR 1.74; 95% CI, 1.08-2.81; P-trend = 0.01). In addition, there was a significant increased risk with higher 16-pathway/parent estrogen metabolite ratio (comparable RR 1.61; 95% CI, 0.99-2.62; P-trend = 0.04). Other pathway ratios were not significantly associated with risk except parent estrogen metabolites/non-parent estrogen metabolites (comparable RR 0.58; 95% CI, 0.35-0.96; P-trend = 0.03). These data suggest that most mid-luteal urinary estrogen metabolite concentrations are not positively associated with breast cancer risk among premenopausal women. The inverse associations with parent estrogen metabolites and the parent estrogen metabolite/non-parent estrogen metabolite ratio suggest that women with higher urinary excretion of parent estrogens are at lower risk. Cancer Res; 72(3); 696-706. | |
dc.language.iso | en_US | |
dc.publisher | American Association for Cancer Research | |
dash.license | LAA | |
dc.title | Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women | |
dc.type | Journal Article | |
dc.description.version | Accepted Manuscript | |
dc.relation.journal | Cancer Research | |
dash.depositing.author | Spiegelman, Donna::37eeac21962b33e4e46e7aedde542849::600 | |
dc.date.available | 2019-09-21T16:12:40Z | |
dash.workflow.comments | 1Science Serial ID 26529 | |
dc.identifier.doi | 10.1158/0008-5472.CAN-11-2507 | |
dash.source.volume | 72;3 | |
dash.source.page | 696 | |